Literature DB >> 25774563

Seroprevalence of anti-Toxoplasma gondii and anti-Borrelia species antibodies in patients with schizophrenia: a case-control study from western Turkey.

Sibel Cevizci1, Merve Celik, Alper Akcali, Demet Gulec Oyekcin, Ozlem Oztürk Sahin, Coskun Bakar.   

Abstract

OBJECTIVES: We examined IgG antibody seroprevalence and risk factors for anti-Toxoplasma gondii and anti-Borrelia sp. in schizophrenic patients.
METHODS: This case-control study included 30 schizophrenic patients and 60 healthy individuals. Serological analyses were identified by using ELISA technique.
RESULTS: In the case group the Toxoplasma seropositivity was 33.3% and Borrelia seropositivity was 13.3%, while in the control group the Toxoplasma positivity was 21.7% and Borrelia seropositivity was 15.0%. There was no significant difference with regard to seroprevalence between the groups (P = 0.232; P = 0.832, respectively). There was statistically significant difference between case and control groups related to hand and kitchen utensil hygiene after dealing with raw meat (P = 0.001).
CONCLUSIONS: Our data showed the rate of Toxoplasma antibodies was higher in the case group, while the rate of Borrelia antibodies was higher in the control group. In both groups the high rates of seropositivity for Toxoplasma gondii and Borrelia sp. is thought to be due to neglect of personal hygiene. The present study also is the first to examine the association between Borrelia sp. and schizophrenia. Further studies are needed to determine whether there is an association between Borrelia sp. and schizophrenia or not.

Entities:  

Keywords:  Borrelia species; Toxoplasma gondii; public health; schizophrenia; zoonosis

Mesh:

Substances:

Year:  2015        PMID: 25774563     DOI: 10.3109/15622975.2015.1012224

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  1 in total

1.  Bacterial infections among patients with psychiatric disorders: Relation with hospital stay, age, and psychiatric diagnoses.

Authors:  Michael Belz; Nico Rehling; Ulrike Schmidt; Jens Wiltfang; Bernhard Kis; Claus Wolff-Menzler
Journal:  PLoS One       Date:  2018-12-04       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.